Search Results - "Simkens, Lieke H.J."

Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group by Kwakman, Johannes J.M, Simkens, Lieke H.J, Mol, Linda, Kok, Wouter E.M, Koopman, Miriam, Punt, Cornelis J.A

“…Abstract Background The frequency of capecitabine-related cardiotoxicity has been reported to be low but includes serious adverse events. We conducted a…”
Get full text

Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy by Simkens, Lieke H.J, Koopman, Miriam, Mol, Linda, Veldhuis, Gerrit Jan, Ten Bokkel Huinink, Daan, Muller, Erik W, Derleyn, Veerle A, Teerenstra, Steven, Punt, Cornelis J.A

“…Abstract Purpose Obesity is associated with an increased risk of development and recurrence of colorectal cancer. However, the role of obesity in advanced…”
Get full text

Optimal duration of systemic treatment in metastatic colorectal cancer by Simkens, Lieke H.J, Koopman, Miriam, Punt, Cornelis J.A

“…PURPOSE OF REVIEWWith the currently available cytotoxic and targeted drugs, metastatic colorectal cancer (mCRC) may be controlled by systemic treatment for a…”
Get full text

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group by Simkens, Lieke H J, MD, van Tinteren, Harm, PhD, May, Anne, PhD, ten Tije, Albert J, MD, Creemers, Geert-Jan M, MD, Loosveld, Olaf J L, MD, de Jongh, Felix E, MD, Erdkamp, Frans L G, MD, Erjavec, Zoran, MD, van der Torren, Adelheid M E, MD, Tol, Jolien, MD, Braun, Hans J J, MD, Nieboer, Peter, MD, van der Hoeven, Jacobus J M, Prof, Haasjes, Janny G, MD, Jansen, Rob L H, MD, Wals, Jaap, MD, Cats, Annemieke, MD, Derleyn, Veerle A, MD, Honkoop, Aafke H, MD, Mol, Linda, MSc, Punt, Cornelis J A, Prof, Koopman, Miriam, Dr

“…Summary Background The optimum duration of first-line treatment with chemotherapy in combination with bevacizumab in patients with metastatic colorectal cancer…”
Get full text

A propensity score‐matched analysis of oncological outcome after systemic therapy for stage IV colorectal cancer: Impact of synchronous ovarian metastases by Meer, Richard, Bakkers, Checca, Erning, Felice N., Simkens, Lieke H. J., Hingh, Ignace H. J. T., Roumen, Rudi M. H.

“…The reported incidence of synchronous and metachronous ovarian metastases (OM) from colorectal cancer (CRC) is ~3.4%. OM from CRC are often considered…”
Get full text

Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era by Wensink, G. Emerens, Elferink, Marloes A. G., May, Anne M., Mol, Linda, Hamers, Patricia A. H., Bakker, Sandra D., Creemers, Geert-Jan, de Groot, Jan Willem B., de Klerk, Gerty J., Haberkorn, Brigitte C. M., Haringhuizen, Annebeth W., Hoekstra, Ronald, Hunting, J. Cornelis B., Kerver, Emile D., Mathijssen-van Stein, Danielle, Polée, Marco B., Pruijt, Johannes F. M., Quarles van Ufford-Mannesse, Patricia, Radema, Sandra, Rietbroek, Ronald C., Simkens, Lieke H. J., Tanis, Bea C., ten Bokkel Huinink, Daan, Tjin-A-Ton, Manuel L. R., Tromp-van Driel, Cathrien S., Troost, Monique M., van de Wouw, Agnes J., van den Berkmortel, Franchette W. P. J., van der Pas, Anke J. M., van der Velden, Ankie M. T., van Dijk, Marjan A., van Dodewaard-de Jong, Joyce M., van Druten, Edith B., van Voorthuizen, Theo, Jan Veldhuis, Gerrit, Verheul, Henk M. W., Vestjens, Hanneke J. H. M. J., Vincent, Jeroen, Kranenburg, Onno W., Punt, Cornelis J. A., Vink, Geraldine R., Roodhart, Jeanine M. L., Koopman, Miriam

“…Background Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm…”
Get full text

Biomarker concordance between primary colorectal cancer and ovarian metastases: a Dutch cohort study by van der Meer, Richard, Jeuken, Judith W. M., Bosch, Steven L., van Erning, Felice N., Simkens, Lieke H. J., de Hingh, Ignace H. J. T., Roumen, Rudi M. H.

“…Purpose The genetic characteristics and mismatch repair (MMR) status of the primary tumor and corresponding metastases in colorectal cancer (CRC) are generally…”
Get full text

Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer by Ligthart, Sjoerd T, Coumans, Frank A W, Bidard, Francois-Clement, Simkens, Lieke H J, Punt, Cornelis J A, de Groot, Marco R, Attard, Gerhardt, de Bono, Johann S, Pierga, Jean-Yves, Terstappen, Leon W M M

“…Presence of circulating tumor cells (CTC) in patients with metastatic breast, colorectal and prostate cancer is indicative for poor prognosis. An automated CTC…”
Get full text

Maintenance treatment in metastatic colorectal cancer by Simkens, Lieke H J, van Tinteren, Harm, Punt, Cornelis J A, Koopman, Miriam

“…In CAIRO3, the poor prognostic group of patients with disease progression before completion of induction treatment were excluded, as were the probably larger…”
Get full text

Implementation, participation and satisfaction rates of a web-based decision support tool for patients with metastatic colorectal cancer by Keikes, Lotte, de Vos-Geelen, Judith, de Groot, Jan Willem B., Punt, Cornelis J.A., Simkens, Lieke H.J., Trajkovic-Vidakovic, Marija, Portielje, Johanneke E.A., Vos, Allert H., Beerepoot, Laurens V., Hunting, Cornelis B., Koopman, Miriam, van Oijen, Martijn G.H.

“…•There is need for additional decision support for mCRC patients in palliative setting.•This study focuses on implementation of a decision support tool for…”
Get full text

Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study by Krens, Lisanne L, Simkens, Lieke H J, Baas, Jara M, Koomen, Els R, Gelderblom, Hans, Punt, Cornelis J A, Guchelaar, Henk-Jan

“…Statins may inhibit the expression of the mutant KRAS phenotype by preventing the prenylation and thus the activation of the KRAS protein. This study was aimed…”
Get full text

Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial by Kurk, Sophie A., Peeters, Petra H. M., Dorresteijn, Bram, Jong, Pim A., Jourdan, Marion, Creemers, Geert‐Jan M., Erdkamp, Frans L. G., Jongh, Felix E., Kint, Peter A. M., Poppema, Boelo J., Radema, Sandra A., Simkens, Lieke H. J., Tanis, Bea C., Tjin‐A‐Ton, Manuel L. R., Van Der Velden, Ankie, Punt, Cornelis J. A., Koopman, Miriam, May, Anne M.

“…Background Low skeletal muscle index (SMI) in metastatic colorectal cancer (mCRC) patients is associated with poor outcomes. The prognostic impact of SMI…”
Get full text

Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group by Kwakman, Johannes J.M., van Werkhoven, Erik, Simkens, Lieke H.J., van Rooijen, Johan M., van de Wouw, Yes A.J., Tije, Albert J. ten, Creemers, Geert-Jan M., Hendriks, Mathijs P., Los, Maartje, van Alphen, Robbert J., Polée, Marco B., Muller, Erik W., van der Velden, Ankie M.T., van Voorthuizen, Theo, Koopman, Miriam, Mol, Linda, Punt, Cornelis J.A.

Get full text

Systemic treatment: maintenance compared with holiday by Punt, Cornelis J A, Simkens, Lieke H J, Koopman, Miriam

“…With the currently available cytotoxic and targeted drugs, metastatic colorectal cancer (mCRC) may be controlled by systemic treatment for a substantial period…”
Get more information

Aging blunts remodeling of the uterine artery during murine pregnancy by van der Heijden, Olivier W H, Essers, Yvonne P G, Simkens, Lieke H J, Teunissen, Quirine G A, Peeters, Louis L H, De Mey, Jo G R, van Eys, Guillaume J J M

“…The progressive increase in uterine blood flow (UBF) during pregnancy is accommodated by morphologic changes in the uterine artery (UA) in a process defined as…”
Get more information